Interleukin
From Proteopedia
(Difference between revisions)
| Line 38: | Line 38: | ||
== Disease == | == Disease == | ||
IL deficiency results in autoimmune disease<ref>PMID:19494218</ref>. | IL deficiency results in autoimmune disease<ref>PMID:19494218</ref>. | ||
| + | |||
| + | ==3D structures of interleukin== | ||
| + | [[Interleukin 3D structures]] | ||
</StructureSection> | </StructureSection> | ||
| Line 73: | Line 76: | ||
**[[3qb1]] - hIL-2 (mutant)<br /> | **[[3qb1]] - hIL-2 (mutant)<br /> | ||
**[[1irl]] – hIL-2 (mutant) - NMR<BR /> | **[[1irl]] – hIL-2 (mutant) - NMR<BR /> | ||
| - | **[[ | + | **[[5m5e]] - hIL-2 + IL-2 receptor β + cytokine receptor common γ<BR /> |
**[[2erj]], [[2b5i]] - hIL-2 + IL-2 receptor α and β + cytokine receptor common γ<BR /> | **[[2erj]], [[2b5i]] - hIL-2 + IL-2 receptor α and β + cytokine receptor common γ<BR /> | ||
**[[1z92]] - hIL-2 + IL-2 receptor α<BR /> | **[[1z92]] - hIL-2 + IL-2 receptor α<BR /> | ||
| Line 80: | Line 83: | ||
**[[1pw6]], [[1py2]], [[1m48]], [[1m49]] – hIL-2 + inhibitor<BR /> | **[[1pw6]], [[1py2]], [[1m48]], [[1m49]] – hIL-2 + inhibitor<BR /> | ||
**[[4nej]], [[4nem]] – hIL-2 + methylfuran carboxylate derivative<BR /> | **[[4nej]], [[4nem]] – hIL-2 + methylfuran carboxylate derivative<BR /> | ||
| + | **[[5lqb]] - hIL-2 + antibody<br /> | ||
**[[4yue]] - mIL-2 + antibody<br /> | **[[4yue]] - mIL-2 + antibody<br /> | ||
**[[4yqx]] - IL-2 + antibody - rat<br /> | **[[4yqx]] - IL-2 + antibody - rat<br /> | ||
| + | **[[4zf7]] – hIL-2 - ferret<BR /> | ||
*IL-3 | *IL-3 | ||
**[[1jli]] – hIL-3 (mutant) – NMR<BR /> | **[[1jli]] – hIL-3 (mutant) – NMR<BR /> | ||
| + | **[[5uv8]], [[5uwc]] – hIL-3 (mutant) + IL-3 receptor α<BR /> | ||
**[[2l3o]] – mIL-3 residues 33-156 (mutant) - NMR | **[[2l3o]] – mIL-3 residues 33-156 (mutant) - NMR | ||
| Line 93: | Line 99: | ||
**[[2cyk]], [[1cyl]], [[1itm]], [[1bbn]], [[1bcn]], [[1iti]], [[1itl]] – hIL-4 - NMR<BR /> | **[[2cyk]], [[1cyl]], [[1itm]], [[1bbn]], [[1bcn]], [[1iti]], [[1itl]] – hIL-4 - NMR<BR /> | ||
**[[2b8x]], [[2b8y]], [[2b8z]], [[2b90]], [[2b91]], [[2d48]], [[1hzi]], [[1hij]] - hIL-4 (mutant) <BR /> | **[[2b8x]], [[2b8y]], [[2b8z]], [[2b90]], [[2b91]], [[2d48]], [[1hzi]], [[1hij]] - hIL-4 (mutant) <BR /> | ||
| + | **[[5fhx]] - hIL-4 + antibody<BR /> | ||
**[[1iar]] - hIL-4 + IL-4 receptor α (mutant) <BR /> | **[[1iar]] - hIL-4 + IL-4 receptor α (mutant) <BR /> | ||
**[[3bpl]] - hIL-4 + IL-4 receptor α + cytokine receptor common γ<BR /> | **[[3bpl]] - hIL-4 + IL-4 receptor α + cytokine receptor common γ<BR /> | ||
| + | **[[6oel]] - hIL-4 + IL-4 receptor α + cytokine receptor common γ + antibody<BR /> | ||
**[[3qb7]] - hIL-4 + cytokine receptor common γ<BR /> | **[[3qb7]] - hIL-4 + cytokine receptor common γ<BR /> | ||
**[[4ydy]] – hIL-4 + darpin<BR /> | **[[4ydy]] – hIL-4 + darpin<BR /> | ||
| Line 111: | Line 119: | ||
**[[1il6]], [[2il6]] – hIL-6 - NMR<BR /> | **[[1il6]], [[2il6]] – hIL-6 - NMR<BR /> | ||
**[[1p9m]] - hIL-6 + IL-6 receptor α and β<br /> | **[[1p9m]] - hIL-6 + IL-6 receptor α and β<br /> | ||
| + | **[[5fuc]] - hIL-6 + IL-6 receptor α + VHH6<br /> | ||
**[[4j4l]] – hIL-6 + internalin B<BR /> | **[[4j4l]] – hIL-6 + internalin B<BR /> | ||
**[[4ni7]], [[4ni9]] – hIL-6 + nucleotide aptamer<BR /> | **[[4ni7]], [[4ni9]] – hIL-6 + nucleotide aptamer<BR /> | ||
| - | **[[4cni]], [[4o9h]] – hIL-6 + antibody<BR /> | + | **[[4cni]], [[4o9h]], [[4zs7]] – hIL-6 + antibody<BR /> |
**[[2l3y]] - mIL-6 residues 27-211 - NMR<br /> | **[[2l3y]] - mIL-6 residues 27-211 - NMR<br /> | ||
**[[1i16]] – IL-6 + IL-6 receptor β - Herpesvirus 8<br /> | **[[1i16]] – IL-6 + IL-6 receptor β - Herpesvirus 8<br /> | ||
| Line 124: | Line 133: | ||
**[[3il8]], [[5d14]], [[4xdx]] – hIL-8 residues 28-99<BR /> | **[[3il8]], [[5d14]], [[4xdx]] – hIL-8 residues 28-99<BR /> | ||
| - | **[[1il8]], [[2il8]] – hIL-8 - NMR<BR /> | + | **[[1il8]], [[2il8]], [[5wdz]] – hIL-8 - NMR<BR /> |
**[[1qe6]], [[1icw]] – hIL-8 (mutant) <BR /> | **[[1qe6]], [[1icw]] – hIL-8 (mutant) <BR /> | ||
**[[1ikl]], [[1ikm]] - hIL-8 (mutant) - NMR<BR /> | **[[1ikl]], [[1ikm]] - hIL-8 (mutant) - NMR<BR /> | ||
| Line 154: | Line 163: | ||
**[[1f42]] - hIL-12 β P40 domain<BR /> | **[[1f42]] - hIL-12 β P40 domain<BR /> | ||
**[[3hmx]] - hIL-12 α and β+ antibody<br /> | **[[3hmx]] - hIL-12 α and β+ antibody<br /> | ||
| + | **[[4oe8]], [[4og9]], [[5njd]] - hIL-12 β + hIL-23 α + antibody<br /> | ||
| + | **[[5mzv]] - hIL-12 β + hIL-23 α + hIL-23 receptor + antibody<br /> | ||
| + | **[[5mxa]] - hIL-12 β + hIL- 23 α<br /> | ||
**[[5mj3]], [[5mj4]] - hIL-12 β + hIL-23 α + alphabody MB3<br /> | **[[5mj3]], [[5mj4]] - hIL-12 β + hIL-23 α + alphabody MB3<br /> | ||
**[[3qwr]] - hIL-12 β + hIL- 23 α + adnectin | **[[3qwr]] - hIL-12 β + hIL- 23 α + adnectin | ||
| Line 163: | Line 175: | ||
**[[3l5w]], [[3l5x]], [[3g6d]], [[4i77]], [[4ps4]] - hIL-13 residues 35-146 + antibody<BR /> | **[[3l5w]], [[3l5x]], [[3g6d]], [[4i77]], [[4ps4]] - hIL-13 residues 35-146 + antibody<BR /> | ||
**[[3lb6]] - hIL-13 + IL-13 receptor α2<BR /> | **[[3lb6]] - hIL-13 + IL-13 receptor α2<BR /> | ||
| - | **[[3bpo]], [[5e4e]] - hIL-13 residues 20-145 + IL-4 receptor α + IL-13 receptor α | + | **[[3bpo]], [[5e4e]] - hIL-13 residues 20-145 + IL-4 receptor α + IL-13 receptor α<br /> |
| + | **[[5l6y]] - hIL-13 + antibody<br /> | ||
*IL-15 | *IL-15 | ||
| Line 179: | Line 192: | ||
**[[4hr9]] - hIL-17A (mutant)<br /> | **[[4hr9]] - hIL-17A (mutant)<br /> | ||
| + | **[[5n92]] - hIL-17A + hIL-17F <br /> | ||
**[[4hsa]] - hIL-17A (mutant) + IL-17A receptor α <br /> | **[[4hsa]] - hIL-17A (mutant) + IL-17A receptor α <br /> | ||
| - | **[[2vxs]] - hIL-17A | + | **[[5nan]] - hIL-17A + hIL-17F + IL-17A receptor α <br /> |
| + | **[[2vxs]], [[4qhu]] - hIL-17A + antibody<BR /> | ||
| + | **[[5vb9]] - hIL-17A + peptide inhibitor<BR /> | ||
| + | **[[5hi5]], [[5hi4]], [[5hi3]], [[5hhx]], [[5hhv]] - hIL-17A + peptide inhibitor + antibody<BR /> | ||
**[[1jpy]] – hIL-17F<BR /> | **[[1jpy]] – hIL-17F<BR /> | ||
**[[3jvf]] - hIL-17F + IL-17 receptor α | **[[3jvf]] - hIL-17F + IL-17 receptor α | ||
| Line 223: | Line 240: | ||
**[[4grw]] - hIL-23 α + + hIL-12 β + nanobody<BR /> | **[[4grw]] - hIL-23 α + + hIL-12 β + nanobody<BR /> | ||
**[[3duh]] - hIL-23 α + hIL-12 β | **[[3duh]] - hIL-23 α + hIL-12 β | ||
| + | |||
| + | *IL-24 | ||
| + | |||
| + | **[[6gg1]] - hIL-24<br /> | ||
| + | **[[6df3]] - hIL-24 + IL—22 receptor α1 + IL-20 receptor β<br /> | ||
*IL-28 | *IL-28 | ||
| - | **[[3hhc]] – hIL-28B | + | **[[3hhc]] – hIL-28B<br /> |
| + | **[[5t5w]] - hIL-28B + IL—10 receptor β + IL-28 receptor α<br /> | ||
*IL-29 | *IL-29 | ||
| Line 247: | Line 270: | ||
**[[4ize]] - hIL-36 γ<br /> | **[[4ize]] - hIL-36 γ<br /> | ||
| + | **[[6p9e]] - hIL-36 g + antagonist<br /> | ||
| + | |||
| + | *IL-37 | ||
| + | **[[6ncu]], [[5hn1]] - hIL-37<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Revision as of 09:03, 3 September 2019
| |||||||||||
3D structures of interleukin
Updated on 03-September-2019
References
- ↑ Dinarello CA. Biology of interleukin 1. FASEB J. 1988 Feb;2(2):108-15. PMID:3277884
- ↑ Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016 Jan;12(1):14-24. doi: 10.1038/nrrheum.2016.166. Epub 2015, Dec 10. PMID:26656658 doi:http://dx.doi.org/10.1038/nrrheum.2016.166
- ↑ Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med. 2002;1(1):19-25. PMID:14720072
- ↑ Shah N, Kammermeier J, Elawad M, Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep. 2012 Oct;12(5):373-9. doi: 10.1007/s11882-012-0286-z. PMID:22890722 doi:http://dx.doi.org/10.1007/s11882-012-0286-z
- ↑ Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23-63. PMID:22428854
- ↑ Eken A, Singh AK, Oukka M. Interleukin 23 in Crohn's disease. Inflamm Bowel Dis. 2014 Mar;20(3):587-95. doi:, 10.1097/01.MIB.0000442014.52661.20. PMID:24481050 doi:http://dx.doi.org/10.1097/01.MIB.0000442014.52661.20
- ↑ Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009 Jun 4;360(23):2426-37. doi: 10.1056/NEJMoa0807865. PMID:19494218 doi:10.1056/NEJMoa0807865
